Could continuing a common heart drug before surgery save lives?

This trial asks whether people with heart failure who take SGLT-2 inhibitors (like dapagliflozin or empagliflozin) should continue the medication right up to cardiac surgery, rather than stopping it three days before as currently recommended. The study will compare outcomes like heart damage, low cardiac output, rehospitalization, and death within 30 days after surgery. About 434 adults scheduled for heart surgery with a heart pump will be randomly assigned to either continue or stop their medication. The goal is to see if keeping the drug on board improves recovery and reduces complications.